文献速递呼吸道感染

严重程度评分指导社区获得性肺炎大环内酯类用药的评估

Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia.
PubMed 文献 · Eur Respir J · 2017-09-10

该研究为四项前瞻性社区获得性肺炎(CAP)数据集的二次分析,共纳入3297例患者,评估CURB-65和肺炎严重指数(PSI)对非典型病原体的预测价值及按风险等级使用大环内酯类对死亡的影响。结果显示两评分对非典型病原体预测价值差(AUC分别为0.37和0.42),且严重程度评分并非大环内酯类治疗反应的显著修饰因素,提示现行据此指导经验性抗生素选择的指南可能缺乏依据。

要点

  • CURB-65和PSI对非典型病原体的预测价值差,AUC分别为0.37和0.42。
  • 按CURB-65或PSI分层,大环内酯类对死亡的影响在轻、中、重度CAP间无显著差异。
  • 严重程度评分不能准确预测大环内酯类治疗反应,据此指导经验性用药可能不合理。

核心结论

  • 严重程度评分不能准确预测CAP患者对大环内酯类治疗的反应,现行据此指导经验性抗生素选择的指南可能缺乏依据。

研究设计与样本

  • 四项独立前瞻性CAP数据集的二次分析,共评估3297例患者。

主要发现

  • CURB-65和PSI对非典型病原体的预测价值差,AUC分别为0.37和0.42。
  • 按CURB-65分层,大环内酯类对死亡的影响在重度与轻度CAP间的交互检验OR=0.74(0.29-1.89)。
  • 按PSI分层,大环内酯类对死亡的影响在重度与轻度CAP间的交互检验OR=3.4(0.055-2.10)。
  • 严重程度评分并非大环内酯类治疗反应的显著修饰因素。

临床怎么用

  • 不应仅凭CURB-65或PSI评分决定CAP患者是否使用大环内酯类。
  • 经验性抗生素选择需综合评估非典型病原体风险,而非依赖严重程度评分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

International guidelines including those in the UK, Japan, Australia and South Africa recommend the avoidance of macrolides in patients with low-severity community-acquired pneumonia (CAP). We hypothesised that severity scores are poor predictors of atypical pneumonia and response to macrolide therapy, and thus, inadequate tools for guiding antibiotic prescriptions.Secondary analysis of four independent prospective CAP datasets was conducted. The predictive values of the CURB-65 and pneumonia severity index (PSI) for clinically important groups of causative pathogens were evaluated. The effect of macrolide use according to risk class was assessed by multivariable analysis. Patients (3297) were evaluated, and the predictive values of CURB-65 and PSI for atypical pathogens were poor (AUC values of 0.37 and 0.42, respectively). No significant differences were noted among the effects of macrolide use on mortality in patients with mild, moderate and severe CAP, according to either CURB-65 (interaction testing severe versus mild disease OR=0.74 (0.29-1.89)) or PSI (severe versus mild disease OR=3.4 (0.055-2.10)), indicating that severity scores were not significant modifiers of response to macrolide therapy.Severity scores did not accurately predict response to macrolide therapy in CAP, suggesting that current guidance to use these tools for empirical antibiotic choices might not be justified.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Singanayagam A, Aliberti S, Cillóniz C, et al. Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia. Eur Respir J. 2017. PMID: 28890433. doi:10.1183/13993003.02306-2016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。